Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
08:45am, Sunday, 10'th Dec 2023
AstraZeneca is shelling out hundreds of millions to position itself to benefit from AI. Its competitors are following suit as the drug industry climbs onto the AI bandwagon.
Is Now the Right Time to Buy AstraZeneca Stock?
07:15am, Sunday, 10'th Dec 2023
AstraZeneca's pipeline is huge, and it's buying more assets to develop too. It's also making a major play to enter the digital healthcare space.
Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 2024
09:12am, Saturday, 09'th Dec 2023
This integrated giant is safer for investors looking to get positioned in the energy sector, has backed up some, and now yields a strong 4.17% dividend.
AstraZeneca, Diageo, Lloyds & other UK Banks: What London's brokers had to say today
10:45am, Wednesday, 06'th Dec 2023
Here's our daily round-up of what's been doing the rounds in the Square Mile.
AstraZeneca and the world according to GARP
08:11am, Wednesday, 06'th Dec 2023
AstraZeneca PLC (LSE:AZN), the Anglo-Swedish pharmaceutical giant, stands as a quintessential example of a 'growth at a reasonable price' (GARP) investment opportunity, according to Bank of America. T
AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why
11:14am, Tuesday, 05'th Dec 2023
JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its top
AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It
10:32am, Tuesday, 05'th Dec 2023
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
01:28am, Sunday, 03'rd Dec 2023
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times re
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
12:53pm, Friday, 01'st Dec 2023
Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.
AstraZeneca CEO says they've reduced emissions by 60%
11:33am, Friday, 01'st Dec 2023
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9 Visit http://www.bloomberg.com for business news & anal
AstraZeneca discontinues phase III trials
03:04am, Friday, 01'st Dec 2023
AstraZeneca PLC (LSE:AZN) has announced the discontinuation of two phase III trials, STABILIZE-CKD and DIALIZE-Outcomes, for its drug Lokelma (sodium zirconium cyclosilicate). This decision stems fro
AstraZeneca to scrap two trials on drug that curbs potassium
02:46am, Friday, 01'st Dec 2023
AstraZeneca on Friday said it would discontinue two late-stage trials looking at the potential benefits of its drug Lokelma in the management of hyperkalaemia across the cardiorenal spectrum.
17 Ideal Pre-Crash Recovery December Divi-Dogs
04:55pm, Thursday, 30'th Nov 2023
September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 p
AstraZeneca needs margin clarity for further upside says Jefferies
09:53am, Monday, 27'th Nov 2023
AstraZeneca PLC (LSE:AZN) fell 0.9% as analysts at Jefferies trimmed estimates and argued that clarity on margins may be needed for further stock upside. The broker, has a buy rating on the Anglo-Sw
Investors Heavily Search AstraZeneca PLC (AZN): Here is What You Need to Know
11:18am, Friday, 24'th Nov 2023
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
